Elliott Geoffrey Playford1, Trent Munro2, Stephen M Mahler3, Suzanne Elliott4, Michael Gerometta2, Kym L Hoger2, Martina L Jones3, Paul Griffin5, Kathleen D Lynch6, Heidi Carroll7, Debra El Saadi7, Margaret E Gilmour4, Benjamin Hughes2, Karen Hughes2, Edwin Huang2, Christopher de Bakker2, Reuben Klein8, Mark G Scher9, Ina L Smith8, Lin-Fa Wang10, Stephen B Lambert6, Dimiter S Dimitrov11, Peter P Gray3, Christopher C Broder12. 1. Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland Brisbane, QLD, Australia. Electronic address: geoffrey.Playford@health.qld.gov.au. 2. Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia. 3. Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia. 4. Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia. 5. Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia; Clinical Tropical Medicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. 6. Child Health Research Centre, Faculty of Medicine, University of Queensland Brisbane, QLD, Australia; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia. 7. Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia. 8. Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia. 9. Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. 10. Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia; Programme in Emerging Infectious Diseases, Duke-National University Medical School, Singapore. 11. Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, PA, USA. 12. Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Abstract
BACKGROUND: The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in healthy adults. METHODS: In this double-blind, placebo-controlled, single-centre, dose-escalation, phase 1 trial of m102.4, we randomly assigned healthy adults aged 18-50 years with a body-mass index of 18·0-35·0 kg/m2 to one of five cohorts. A sentinel pair for each cohort was randomly assigned to either m102.4 or placebo. The remaining participants in each cohort were randomly assigned (5:1) to receive m102.4 or placebo. Cohorts 1-4 received a single intravenous infusion of m102.4 at doses of 1 mg/kg (cohort 1), 3 mg/kg (cohort 2), 10 mg/kg (cohort 3), and 20 mg/kg (cohort 4), and were monitored for 113 days. Cohort 5 received two infusions of 20 mg/kg 72 h apart and were monitored for 123 days. The primary outcomes were safety and tolerability. Secondary outcomes were pharmacokinetics and immunogenicity. Analyses were completed according to protocol. The study was registered on the Australian New Zealand Clinical Trials Registry, ACTRN12615000395538. FINDINGS:Between March 27, 2015, and June 16, 2016, 40 (52%) of 77 healthy screened adults were enrolled in the study. Eight participants were assigned to each cohort (six received m102.4 and two received placebo). 86 treatment-emergent adverse events were reported, with similar rates between placebo and treatment groups. The most common treatment-related event was headache (12 [40%] of 30 participants in the combined m102.4 group, and three [30%] of ten participants in the pooled placebo group). No deaths or severe adverse events leading to study discontinuation occurred. Pharmacokinetics based on those receiving m102.4 (n=30) were linear, with a median half-life of 663·3 h (range 474·3-735·1) for cohort 1, 466·3 h (382·8-522·3) for cohort 2, 397·0 h (333·9-491·8) for cohort 3, and 466·7 h (351·0-889·6) for cohort 4. The elimination kinetics of those receiving repeated dosing (cohort 5) were similar to those of single-dose recipients (median elimination half-time 472·0 [385·6-592·0]). Anti-m102.4 antibodies were not detected at any time-point during the study. INTERPRETATION: Single and repeated dosing of m102.4 were well tolerated and safe, displayed linear pharmacokinetics, and showed no evidence of an immunogenic response. This study will inform future dosing regimens for m102.4 to achieve prolonged exposure for systemic efficacy to prevent and treat henipavirus infections. FUNDING: Queensland Department of Health, the National Health and Medical Research Council, and the National Hendra Virus Research Program.
RCT Entities:
BACKGROUND: The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in healthy adults. METHODS: In this double-blind, placebo-controlled, single-centre, dose-escalation, phase 1 trial of m102.4, we randomly assigned healthy adults aged 18-50 years with a body-mass index of 18·0-35·0 kg/m2 to one of five cohorts. A sentinel pair for each cohort was randomly assigned to either m102.4 or placebo. The remaining participants in each cohort were randomly assigned (5:1) to receive m102.4 or placebo. Cohorts 1-4 received a single intravenous infusion of m102.4 at doses of 1 mg/kg (cohort 1), 3 mg/kg (cohort 2), 10 mg/kg (cohort 3), and 20 mg/kg (cohort 4), and were monitored for 113 days. Cohort 5 received two infusions of 20 mg/kg 72 h apart and were monitored for 123 days. The primary outcomes were safety and tolerability. Secondary outcomes were pharmacokinetics and immunogenicity. Analyses were completed according to protocol. The study was registered on the Australian New Zealand Clinical Trials Registry, ACTRN12615000395538. FINDINGS: Between March 27, 2015, and June 16, 2016, 40 (52%) of 77 healthy screened adults were enrolled in the study. Eight participants were assigned to each cohort (six received m102.4 and two received placebo). 86 treatment-emergent adverse events were reported, with similar rates between placebo and treatment groups. The most common treatment-related event was headache (12 [40%] of 30 participants in the combined m102.4 group, and three [30%] of ten participants in the pooled placebo group). No deaths or severe adverse events leading to study discontinuation occurred. Pharmacokinetics based on those receiving m102.4 (n=30) were linear, with a median half-life of 663·3 h (range 474·3-735·1) for cohort 1, 466·3 h (382·8-522·3) for cohort 2, 397·0 h (333·9-491·8) for cohort 3, and 466·7 h (351·0-889·6) for cohort 4. The elimination kinetics of those receiving repeated dosing (cohort 5) were similar to those of single-dose recipients (median elimination half-time 472·0 [385·6-592·0]). Anti-m102.4 antibodies were not detected at any time-point during the study. INTERPRETATION: Single and repeated dosing of m102.4 were well tolerated and safe, displayed linear pharmacokinetics, and showed no evidence of an immunogenic response. This study will inform future dosing regimens for m102.4 to achieve prolonged exposure for systemic efficacy to prevent and treat henipavirus infections. FUNDING: Queensland Department of Health, the National Health and Medical Research Council, and the National Hendra Virus Research Program.
Authors: Jinhui Dong; Robert W Cross; Michael P Doyle; Nurgun Kose; Jarrod J Mousa; Edward J Annand; Viktoriya Borisevich; Krystle N Agans; Rachel Sutton; Rachel Nargi; Mahsa Majedi; Karla A Fenton; Walter Reichard; Robin G Bombardi; Thomas W Geisbert; James E Crowe Journal: Cell Date: 2020-12-10 Impact factor: 41.582
Authors: Zhaoqian Wang; Ha V Dang; Moushimi Amaya; Yan Xu; Randy Yin; Lianying Yan; Andrew C Hickey; Edward J Annand; Bethany A Horsburgh; Peter A Reid; Ina Smith; John-Sebastian Eden; Kai Xu; Christopher C Broder; David Veesler Journal: Proc Natl Acad Sci U S A Date: 2022-05-26 Impact factor: 12.779
Authors: Michael A MacDonald; Matthias Nöbel; Verónica S Martínez; Kym Baker; Evan Shave; Peter P Gray; Stephen Mahler; Trent Munro; Lars K Nielsen; Esteban Marcellin Journal: MAbs Date: 2022 Jan-Dec Impact factor: 6.440
Authors: Yvonne Jing Mei Liew; Puteri Ainaa S Ibrahim; Hui Ming Ong; Chee Ning Chong; Chong Tin Tan; Jie Ping Schee; Raúl Gómez Román; Neil George Cherian; Won Fen Wong; Li-Yen Chang Journal: Microorganisms Date: 2022-06-06
Authors: Ha V Dang; Robert W Cross; Viktoriya Borisevich; Zachary A Bornholdt; Brandyn R West; Yee-Peng Chan; Chad E Mire; Sofia Cheliout Da Silva; Antony S Dimitrov; Lianying Yan; Moushimi Amaya; Chanakha K Navaratnarajah; Larry Zeitlin; Thomas W Geisbert; Christopher C Broder; David Veesler Journal: Nat Struct Mol Biol Date: 2021-04-29 Impact factor: 15.369
Authors: Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust Journal: Front Cell Infect Microbiol Date: 2021-07-07 Impact factor: 5.293
Authors: Moushimi Amaya; Han Cheng; Viktoriya Borisevich; Chanakha K Navaratnarajah; Roberto Cattaneo; Laura Cooper; Terry W Moore; Irina N Gaisina; Thomas W Geisbert; Lijun Rong; Christopher C Broder Journal: Antiviral Res Date: 2021-05-30 Impact factor: 10.103
Authors: Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem Journal: Front Immunol Date: 2020-08-28 Impact factor: 7.561